Moderna slips

Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.
Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Moderna slips as Goldman Sachs downgrades on revenue outlook
Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Read more here.
Moderna downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance
S&P 500 Gains and Losses Today: Moderna Stock Plunges After Analyst Downgrade
Key Takeaways The S&P 500 fell 0.5% on Wednesday, Jan. 29, as the Federal Reserve held interest rates steady in a move widely expected by the financial markets.Goldman Sachs analysts downgraded Moderna stock and slashed their price target,
Moderna Stock Falls on Vaccine Revenue Concerns
If these pre-market losses hold, Moderna stock could erase part of its 8.1% year-to-date lead and deepen its 57.1% year-over-year loss. The equity may also slip below a critical technical level -- its 20-day moving average -- which could pressure it toward its Jan.
Moderna Stock Is Sliding Wednesday: Here's Why
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
Is Moderna Stock a Buy?
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
dermatologyadvisor2d
Moderna Receives $590M From HHS to Develop Bird Flu Vaccine
The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.
Decoding Moderna's Options Activity: What's the Big Picture?
Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...
Moderna Hold Recommendation Amid Reduced Revenue Projections and Price Target
In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...
Where Will Moderna Be in 3 Years?
Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...
FiercePharma2d
Moderna, Novo Nordisk slammed for breaching UK drug marketing code yet again
Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...
Hosted on MSN2d
Here's What to Expect From Moderna's Next Earnings Report
Moderna, Inc. (MRNA), headquartered in Cambridge, Massachusetts, is a leading biotechnology company committed to pioneering ...